The stock of Geron Corp. (NASDAQ:GERN) last traded at $3.93, down -5.07% from the previous session.
GERN stock price is now 34.83% away from the 50-day moving average and 63.81% away from the 200-day moving average. The market capitalization of the company currently stands at $2.31B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $4.50, Robert W. Baird recently Downgraded its rating from Outperform to Neutral for Geron Corp. (NASDAQ: GERN). On April 29, 2024, TD Cowen recently initiated its ‘Buy’ rating on the stock quoting a target price of $10, while ‘Needham’ rates the stock as ‘Buy’
In other news, O’Farrell Elizabeth G., Director bought 6,607 shares of the company’s stock on Aug 24 ’23. The stock was bought for $15,064 at an average price of $2.28. Upon completion of the transaction, the Director now directly owns 7,407 shares in the company, valued at $29109.51. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 24 ’23, Director O’Farrell Elizabeth G. bought 6,579 shares of the business’s stock. A total of $15,000 was incurred on buying the stock at an average price of $2.28. This leaves the insider owning 26,220 shares of the company worth $0.1 million. A total of 18.49% of the company’s stock is owned by insiders.
During the past 12 months, Geron Corp. has had a low of $1.64 and a high of $4.30. As of last week, the company has a debt-to-equity ratio of 0.35, a current ratio of 3.16, and a quick ratio of 3.16.
According to the Biotechnology Company, earnings per share came in at -0.07, beating analysts’ expectations of -0.1 by 0.03. This compares to -$0.11 EPS in the same period last year. The net profit margin was -77691.14% and return on equity was -112.29% for GERN. The company reported revenue of $23000.0 for the quarter, compared to $0.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -77.67 percent. For the current quarter, analysts expect GERN to generate $20k in revenue.
